Orthostatic Hypotension: Which Medicines Need a Review?

How do clinicians investigate dizziness on standing?

Harvard Health's October 1 article discusses clinician-supervised reductions in cardiovascular medication. One practical issue within that discussion is how to investigate dizziness before changing treatment: symptoms alone cannot establish which medicine, if any, is responsible. [Harvard Health coverage](https://www.health.harvard.edu/heart-health/deprescribing-heart-medications).

Orthostatic hypotension generally means a sustained fall of at least 20 mmHg in systolic pressure or 10 mmHg in diastolic pressure within three minutes of standing. NICE recommends measuring blood pressure while lying down, or seated when necessary, and again after standing for at least one minute when symptoms suggest a postural drop. A qualifying fall should prompt assessment of possible causes, including medication. Persistent symptoms can warrant further assessment even when an initial measurement does not confirm the condition. [NICE recommendations](https://www.nice.org.uk/guidance/ng136/chapter/recommendations).

Which medicines can contribute to orthostatic hypotension?

The American Heart Association's scientific statement highlights medicines outside hypertension treatment, including amitriptyline, trazodone, dopaminergic drugs, and tamsulosin. Some interfere with the nervous system or vascular responses that help maintain pressure during standing. Trazodone's alpha-blocking activity is one example. A medication review therefore needs to consider prescriptions from every clinician. [AHA scientific statement](https://doi.org/10.1161/HYP.0000000000000236).

The statement recommends identifying symptom patterns and triggers, addressing aggravating factors, and tailoring the antihypertensive regimen. Depending on the cause, a clinician may consider substitution or dose adjustment. Treatment must also account for high blood pressure while resting, which can coexist with low pressure while standing. Patients should discuss changes with their prescriber instead of stopping medicines themselves. [AHA treatment guidance](https://doi.org/10.1161/HYP.0000000000000236).

Does a postural blood pressure drop mean treatment should be reduced?

A 2023 individual participant meta-analysis in JAMA examined nine randomized trials involving 29,235 adults. More intensive blood pressure treatment or active therapy reduced the combined risk of cardiovascular disease or death, with no evidence that baseline orthostatic hypotension changed the treatment effect. The findings support maintaining effective hypertension care when a postural drop is detected without symptoms. [JAMA meta-analysis](https://jamanetwork.com/journals/jama/fullarticle/2810698).

Those results have limits. Participants with postural drops were not necessarily symptomatic, and trial enrollment may have underrepresented frail people. The analysis therefore cannot settle treatment decisions for someone experiencing recurrent dizziness, fainting, or falls. NICE advises using standing blood pressure to guide treatment targets when a significant postural drop or symptoms are present. Clinical decisions need both measurements and the patient's experience. [Study limitations](https://jamanetwork.com/journals/jama/fullarticle/2810698), [NICE treatment guidance](https://www.nice.org.uk/guidance/ng136/chapter/recommendations).